Immunomodulatory drugs (IMiDs) including lenalidomide and pomalidomide bind cereblon (CRBN) and activate the CRL4 CRBN ubiquitin ligase to trigger proteasomal degradation of the essential transcription factors IKZF1 and IKZF3 and multiple myeloma (MM) cytotoxicity. We have shown that CRBN is also targeted for degradation by SCF Fbxo7 ubiquitin ligase. In the current study, we explored the mechanisms underlying sensitivity of MM cells to IMiDs using genome-wide CRISPR-Cas9 screening. We validate that CSN9 signalosome complex, a deactivator of Cullin-RING ubiquitin ligase, inhibits SCF Fbxo7 E3 ligase-mediated CRBN degradation, thereby conferring sensitivity to IMiDs; conversely, loss of function of CSN9 signalosome activates SCF Fbxo7 complex, thereby enhancing degradation of CRBN and conferring IMiD resistance. Finally, we show that pretreatment with either proteasome inhibitors or NEDD8 activating enzyme (NAE) inhibitors can abrogate degradation and maintain levels of CRBN, thereby enhancing sensitivity to IMiDs. These studies therefore demonstrate that CSN9 signalosome complex regulates sensitivity to IMiDs by modulating CRBN expression.
Introduction
Multiple myeloma (MM) is characterized by the infiltration of abnormal plasma cells in bone marrow and represents 1% of all cancers and 2% of blood cancers. Both genetic and environmental/host factors have been implicated in progression of monoclonal gammopathy of undetermined significance (MGUS) to smoldering MM and active MM requiring therapy. [1, 2] Major improvements in patient outcome have resulted from the development of high dose therapy and autologous stem cell transplantation (ASCT), [3] [4] [5] as well as the development of novel agents targeting the tumor in its bone marrow microenvironment including: immunomodulatory drugs (IMiDs) thalidomide, lenalidomide and pomalidomide; [6] [7] [8] proteasome inhibitors (PIs) bortezomib, carfilzomib, and ixazomib; [9] [10] [11] [12] monoclonal antibodies daratumumab and elotuzumab; [13] [14] [15] and histone deacetylase inhibitor panobinostat. [16] Integration of novel therapies as induction before and maintenance after ASCT has achieved the highest extents and frequency of response. [17] In spite of this progress, MM commonly acquires resistance leading to clinical relapse, highlighting the importance of defining mechanisms of sensitivity versus resistance to these agents.
Recent studies have delineated the mechanism of action of IMiDs. The IMiD thalidomide (Thal), which tragically resulted in phocomelia when prescribed as a sedative to treat morning sickness of pregnant women 50 years ago, targets CRBN, [18] a substrate specificity factor of Cullin4 Ring Ligase (CRL4). CRL4 CRBN ubiquitin ligase targets the large conductance Ca 2+ -activated potassium (BK) channels [19] and the CLC-1 chloride channels [20] for ubiquitination, and when mutated is associated with autosomal recessive non-syndromic mental retardation. [21] The teratogenicity of Thal may be related to binding to CRBN and inhibition of CRL4 CRBN ubiquitin ligase activity. [18] Importantly, the IMiDs thalidomide, lenalidomide, and pomalidomide have been shown to target and trigger cytotoxicity against MM cells in their bone marrow microenvironment in preclinical studies, and to have remarkable clinical efficacy when used as initial, salvage, and maintenance therapy in MM. [22, 23] These IMiDs activate the CRL4 CRBN ubiquitin ligase to target B-cell specific transcription factors IKZF1 and IKZF3, which are essential for MM cell survival, for ubiquitination, and destruction. [24, 25] Similarly, lenalidomide induces ubiquitination and degradation of another substrate casein kinase 1A1 (CK1α) in myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)). [26] Mechanistically, IMiDs dock to an exposed surface of CRBN distant from CRL4, [27, 28] and the complex then recruits and binds these substrates. [29] We recently showed that CRBN is also a substrate for another ubiquitin ligase SCF Fbxo7 . [30] Most recently, we have identified p53-related protein kinase as another substrate of IMiDs and promising therapeutic target in MM. [31] To date however, mechanisms regulating CRBN and sensitivity to IMiDs have not been defined.
In the present study, we performed a CRISPR-Cas9 based genome-wide screening in MM cells to identify and delineate mechanisms of IMID sensitivity. We identify and validate mechanisms whereby CSN9 signalosome (CSN) subunits modulate CRBN expression levels and sensitivity to IMiDs in MM. These studies also delineate mechanisms underlying the observed enhanced clinical efficacy of IMiDs when used in combination with PIs.
Materials and methods

CRISPR-Cas9 library screening
Library amplification
The human GeCKOv2 sgRNA libraries were purchased from Addgene and amplified according to the protocol provided by Zhang's lab (www.genome-engineering.org). Briefly, we conducted 4 electroporations using 8 µl of 50 ng/µL GeCKOv2 A or B sub-library in Lucigen Endura electrocompetent cells, with yield of 2 mg plasmids for each sub-library. SgRNAs from the original and amplified libraries were further amplified using a two-step PCR, followed by a Miseq 150 deep-sequencing for quality control.
Lentivirus production
To produce lentivirus, 4.5 × 10 8 293 T cells (Thermo Fisher #R700-07) were harvested and reverse-transfected into twenty-five T-150 flasks. For each flask, 20 µg GeCKOv2 A or B library plasmid, 15 µg psPAX2 (Addgene #12260), and 10 µg pMD2.G (Addgene #12259) diluted in 3 ml Opti-MEM were combined with 150 µL Lipofectamine 2000 diluted in 3 ml Opti-MEM. The mixture was left for 20 min and then added to the cells. 12 h after transfection, the media was replaced by fresh culture media. Virus supernatant was collected 72 h post-transfection, followed by centrifugation at 2000 rpm for 10 min to pellet cell debris. Filtration was then performed with a 0.45 µm low protein binding membrane (Millipore #SE1M003M00), followed by ultra-centrifugation at 25,000 rpm at 4°C for 2 h to pellet virus. The pellets of virus were resuspended and aliquots stored at −80°C. For virus titration, HCT116 cells were seeded (1 × 10 5 per well in 6-well plates) one day before transduction. Lentivirus stock was thawed and diluted (10 −3 to 10
) for transduction. Cells were incubated with virus overnight, then in culture media for 24 h followed by puromycin selection for 5 days, before staining by crystal violet.
Cell transduction
Virus was first tested to achieve an MOI of 0.3-0.4 in MM.1S cells, and 75 µl virus was used for large-scale spin-infection of MM.1S cells (3 × 10 6 ). A total of 2.1 × 10 8 MM.1S cells (70 wells per 12-well plate, 10 wells for transfection efficiency control) were transduced with concentrated virus (5.25 ml), attaining transduction efficiency of 25% (700 cells per lentiCRISPRv2 construct). Puromycin was added to cells 24 h after transduction, and maintained for 7 days. Subsequently, 4 × 10 7 cells were collected for base-line genomic DNA analysis. The remaining cells were split for pomalidomide versus vehicle control treatment. The starting drug concentrations were 75 nM GeCKO v2A and 100 nM GeCKO v2B, the IC70 for MM.1S cells, and drug was refreshed every 3 days. On Days 7, 14 and 21 after drug treatment, 4 × 10 7 cells were removed from either drug group or vehicle control group for analysis.
Genomic DNA sequencing
Genomic DNA extraction (QIAGEN cat#12362) and PCR amplification were performed according to Zhang's protocol. In brief, for each sample we performed at least 40 separate 50 µl reactions, with 4 µg genomic DNA in each reaction, for the 1st step PCR. The 2nd PCR was done in 4 separate 50 µl reactions, with 5 µl of combined amplicons from the first PCR. The primers for the 1st PCR are the same as published, and the primers for the 2nd PCR are below:
F2: (1-9 bp variable length sequence) tcttgtggaaaggac gaaacaccg;
R2: (1-9 bp variable length sequence) tgtgggcgatgtgc gctct;
Resulting amplicons were purified for sequencing library construction with Illumina kits, followed by Hiseq 2500 Rapid PE75 deep sequencing.
Data processing and initial analysis
Raw reads and normalized reads were obtained as Zhang et al. described. Genes were identified by the algorithm, as described above.
Cell lines
HEK 293T, MM1.S, and NCI-H929 cell lines were obtained from American Type Culture Collection (ATCC). OPM2 cell line was obtained from Leibniz-Institut DSMZ. Cells were cultured in media recommended by ATCC, maintained at 37°C in 5% CO 2 condition, and regularly tested for mycoplasma contamination.
cDNA and plasmids
Full-length CRBN was PCR amplified and sub-cloned into pXF4H expression vector between the XbaI and HindIII restriction sites. Full-length Fbxo7 sequences was subcloned into pcDNA3.1(-)-Myc vector between the XbaI and HindIII restriction sites. Full length and truncations of Fbxo7 or CRBN were amplified and sub-cloned into pXF6F expression vector between the XbaI and HindIII restriction sites.
Compounds and antibodies
bortezomib (S1013), lenalidomide (S1029), pomalidomide (S1567), and MLN4924 (S7109) were purchased from Selleck Chem; all were dissolved in DMSO. Anti-Flag (F3165; Sigma-Aldrich), anti-HA (H6908; H3663; SigmaAldrich), anti-Myc (2272; Cell Signaling Technology), antiCul1 (AP16324b; Abgent), anti-β-actin (5779-1; Epitomics), anti-actin (1844-1; Epitomics), anti-TRIP15 (ab155774; Abcam), anti-CSN6 (NBP1-79752), anti-JAB1 (ab182756; Abcam), anti-CSN7B (ab133548; Abcam), anti-CSN7A (AP12810b; Abgent), anti-CSN8 (AP14987a; Abgent), anti-Fbxo7 (ab57037; Abcam), anti-IKZF3 (ab139408; Abcam), anti-IKZF1 (sc-13039; Santa Cruz), anti-Nedd8 (ab81264; Abcam), anti-HA agarose (E6779; Sigma-Aldrich), anti-Myc agarose (E6654; Sigma-Aldrich), and anti-CRBN (SAB045910; Sigma-Aldrich) were purchased and used according to the manufacturers' recommendations. Secondary antibodies included goat anti-mouse IgG-HRP (sc-2005; Santa Cruz) and Goat anti-rabbit IgG-HRP (sc-2004; Santa Cruz).
Q-PCR
Relative levels of CSN4 transcripts was determined with GAPDH as housekeeping gene using SYBR Green (Life Technology). Primers are listed below:
CSN4 forward: TTCGAGCGGCTCTCATAAAGA, reverse: CGAGATCACGAGACT-GACATTCT; GAPDH forward: AGGTGAAGGTCGGAGTCAAC, reverse: CG CTCC-TGGAAGATGGTGAT.
Western blot
Protein lysates were separated by SDS-PAGE and transferred onto PVDF membranes. Blots were blocked in 5% non-fat dry milk, and incubated with primary antibodies in 5% BSA at 4°C overnight. Blots were then washed 3 times with 1 × TBS-T, prior to incubation with secondary antibodies for 1 h. Detection was performed using chemoluminescent substrates (Thermo Scientific).
Co-immunoprecipitation
HEK 293T or MM cells were transiently transfected with indicated plasmids, and then lysed in lysis buffer supplemented with complete protease inhibitors (Roche). After centrifugation at 13,000 rpm for 20 min, supernatants were subjected to immunoprecipitation by incubation with anti-HA Affinity Gel or anti-Myc Affinity Gel (Sigma) for 4 h or overnight at 4°C. The samples were then washed 3 times with lysis buffer, and the immunoprecipitates were separated by SDS-PAGE and analyzed by Western blot.
Lentiviral sgRNA vectors and infection
Oligonucleotides (Supplementary Table S1 ) targeting different genes were annealed and sub-cloned into lentiCRISPRv2 vectors. The sgRNA vectors were then transfected into HEK 293FT cells, together with pVSVg and psPAX2 vectors, using Lipofectamine 2000. Media was replaced at 24 h, and the viral supernatant was collected 72 h post-transfection, with ultra-centrifugation at 25,000 rpm at 4°C for 2 h.
For viral infection, MM cells were seeded in 12-well plates supplemented with 1 μg/ml Polybrene (Sigma). Cells were centrifuged at 2000 rpm for 2 h at 37°C; media was then aspirated, and fresh media was added, excluding polybrene.
Viability assay
MM cells were seeded in 96-well plates and treated with bortezomib and lenalidomide or pomalidomde at indicated concentrations and time intervals. Total cellular ATP content was assessed using CellTiter-Glo® Luminescent Cell Viability Assay (Promega), according to the manufacturer's protocol. Luminescence was detected in a multimode detector DTX880 (Beckman Coulter).
Gene expression correlation analysis
We downloaded the gene expression profiles in 304 patients with newly diagnosed and previously treated MM from the Multiple Myeloma Research Consortium (MMRC). The expression signals have been median centered and log2 normalized. The Pearson correlation coefficient, and its significance for each paired gene was calculated.
Results
Genome-wide CRISPR-Cas9 screen for IMiDs sensitivity
To delineate the mechanism underlying IMiDs sensitivity, we first performed genome-wide knockout screening in MM.1S, an IMiDs-sensitive MM cell line, using a CRISPRCas9 GeCKOv2 library [32, 33] Figure S1c) , and then harvested after 1, 2, and 3 weeks (Fig. 1a) . Deep sequencing of embedded sgRNA barcodes showed coverage of at least 100 reads for more than 98% sgRNAs in cells prior to pomalidomide treatment (Supplementary Figure S1d) , and an average total 1.6 × 10 8 sgRNA reads scored at each time point (Supplementary Figure S1e) . Enrichment of a few sgRNA sequences was observed after 2 weeks pomalidomide treatment (Supplementary Figure S1f) .
Twenty-eight (28) genes and one microRNA ( Fig. 1b ; Supplementary Table S2) were identified in viable cells based upon the following criteria: (1) time-dependent accumulation; (2) at least a four-fold increase in drugtreated cells compared to vehicle control cells at 21 days; and (3) at least 2 unique sgRNA sequences against each gene meeting criteria 1 and 2. All six sgRNAs targeting CRBN were identified (Fig. 1b, c) , consistent with CRBN as the direct target of pomalidomide [28, 29] and required for IMiDs-induced MM cell cytotoxicity. [34, 35] 
Degradation of IKZF3 induced by IMiDs is inhibited by CSN knockout
Among the genes identified by CRISPR-based genomewide knockout screening, 7 of 9 CSN9 signalosome (CSN) subunits [36] were found to be required for MM cell (Fig. 1b, c) and are the main focus of this study. To validate the functional importance of these genes mediating pomalidomide and lenalidomide-induced cytotoxicity, sgRNAs against CRBN and these seven genes were individually cloned into the Cas9 lentiviral vector, and then re-introduced into MM.1S cells (Supplementary Figures S2a and b) . Importantly, knockout of each CSN gene confers partial resistance to pomalidomide and lenalidomide (Fig. 2a) . CSN inactivates the cullin family ubiquitin ligases by removing the ubiquitin-like Nedd8 protein, which is covalently attached to cullins. [37] [38] [39] Deletion of these CSN subunits in MM cells led to a dramatic decrease of CRBN protein levels in MM.1S cells (Fig. 2b) , except for CSN7A which has a mutually exclusive role with CSN7B. [40] Moreover, pomalidomide-induced IKZF3 degradation was also abrogated by CSN6 knockout (Fig. 2c) . We confirmed that deletion of CSN2 or CSN6 in other MM cell lines OPM2 and H929 similarly decreased CRBN levels, decreased IKZF3 degradation, and conferred pomalidomide resistance (Supplementary Figures S3a-c) , Finally, CRBN gene expression was positively correlated with expression of CSN subunits in 304 patients with newly diagnosed and previously treated MM (Supplementary Figure S4) , indicating potential clinical relevance. Taken together, our CRISPR screening therefore identified CRBN regulation mediated by CSNs as key determinants of IMiDs sensitivity in MM cells.
CSN inhibits the degradation of CRBN by SCF Fbxo7
We have previously shown that CRBN can be targeted and degraded by SCF Fbxo7 E3 ubiquitin ligase. [30] We here demonstrate that CRBN interacts with CRL4 and SCF Fbxo7 at distinct domains (Supplementary Figures S5a-c ). We therefore next tested whether CSNs prevent SCF Fbxo7 from targeting CRBN for degradation. We found that cul1 neddylation level was significantly increased in CSN2 knockout MM cells (Fig. 3a) , consistent with a role of CSNs in negatively regulating SCF ubiquitin ligase activity. [38, 41] Importantly, deletion of either Cul1 (Fig. 3b) or Fbxo7 (Fig. 3c) completely restored CRBN protein levels in CSN2 or CSN6 knockout MM cells to those found in wild type cells; and importantly, re-sensitized these CSN knockout MM cells to pomalidomide-induced cytotoxicity (Fig. 3d,  e) . These studies indicate a role for CSNs in negatively regulating SCF Fbxo7 E3 ligase activity targeting CRBN for degradation.
Synergy between bortezomib or MLN4924 and IMiDs by sequential treatment
Since CRBN turnover is controlled by a SCF ubiquitin ligase, we next hypothesized that proteasome inhibitor bortezomib, in addition of its inherent anti-MM activity, might stabilize CRBN and thereby enhance IMiDs-induced MM cell cytotoxicity. To address this hypothesis, we pretreated CSN6 knockout cells with bortezomib to prevent SCF Fbxo7 -mediated CRBN degradation, prior to treatment with pomalidomide. This sequential treatment enhanced CRBN levels, as well as pomalidomide-induced degradation of IKZF3 and cell death (Fig. 4a) . We and others have shown that bortezomib and lenalidomide combination therapy mediate synergistic cytotoxicity in preclinical studies, as well as high frequency and extent of response to treat newly diagnosed and relapsed MM. [17] In the clinic, bortezomib is administered to MM patients either twice or once weekly, whereas lenalidomide is taken every day, [42] suggesting that sequential effects of bortezomib followed by lenalidomide may also be operative in the clinic. We confirmed synergistic cytotoxicity in MM.1S and OPM2 MM cells treated sequentially with bortezomib followed by pomalidomide (Fig. 4b) . Of note, sequential treatment with MLN4924 followed by pomalidomide similarly increased CRBN levels, decreased IKZF1/3 levels, and triggered synergistic MM cytotoxicity (Fig. 4c) .
Taken together, these data indicate that CSN regulated CRBN turnover mediated by SCF Fbxo7 critically regulates CRBN degradation and pomalidomide sensitivity in MM cells. Moreover, either bortezomib or MLN4924 maintains CRBN levels and confers sensitivity to subsequent IMiDs treatment, which may underlie synergistic preclinical cytotoxicity and clinical efficacy of these combination therapies in MM. [43] Discussion RNA-guided CRISPR-Cas9 has been a powerful tool to introduce mutations at specific sites in the genome. [44, 45] Recently, this method has been applied to interrogate gene function on a genome-wide scale, with several advantages relative to RNA interference technology. [33, 46] In the current study, we explored the mechanisms underlying sensitivity versus resistance of MM cells to IMiDs using this genome-wide knockout screen, and identified many genes that are critically required for sensitivity to pomalidomide in MM cells. From our screening, we showed that inactivation of seven of nine CSN subunits confer IMiDs resistance. CSN subunits negatively regulate the activities of all cullin ubiquitin ligases by deneddylating cullins, [37, 38] and are deregulated in many types of cancer. [47] Importantly, here we validated that knockout of 6 CSNs decrease CRBN level and confers resistance to IMiDsinduced MM cytotoxicity. SCF E3 ligases are the largest family of ubiquitin ligases, and regulate many biological process including signal transduction, cell proliferation, and genomic stability. [48] The F-box proteins, as adapters of the SCF complex, determine substrate specific of these E3 ligases, which have an important role in cancer. [49] Importantly, CRBN is targeted and degraded by SCF Fbxo7 E3 ligase. [30] In the current study, we show that CSN knockout increases the activity of SCF Fbxo7 , thereby enhancing degradation of CRBN and conferring resistance to IMiDs. Our results highlight the importance of evaluating the impact of novel IMiDs and derivatives on SCF Fbxo7 activities. Combination treatment with proteasome inhibitor bortezomib or neddylation inhibitor MLN4924 with IMiDs has demonstrated increased MM cytotoxicity in preclinical studies, as well as remarkable extent and frequency of clinical responses. Our study has begun to identify mechanisms underlying these enhanced activities. Here we show that pretreatment with either PI bortezomib or MLN4924 maintains increased levels of CRBN by counteracting SCF Fbxo7 -targeted CRBN degradation, thereby conferring sensitivity to subsequent IMiDs (Poma or Lena) induced cytotoxicity.
Taken together, our genome-scale CRISPRCas9 screening has identified the novel molecular mechanisms regulating sensitivity of MM cells to IMiDs (Fig. 5) . CSN9 signalosome complex inhibits the activity of SCF Fbxo7 E3 ligase-related CRBN degradation; conversely, loss of function of CSN9 signalosome activates SCF Fbxo7 complex, enhances degradation of CRBN, and confers IMiD resistance. Finally, proteasome inhibitors or NAE inhibitors can suppress degradation and maintain levels of CRBN, thereby enhancing sensitivity to IMiDs. These studies identify targets for novel therapeutics to enhance sensitivity to or overcome resistance to IMiDs. 
